Total Testosterone: Which Tests to Order Alongside

What Total Testosterone Actually Measures

Total testosterone captures every testosterone molecule in the blood, both the fraction bound to proteins and the small fraction circulating freely. Roughly 44% binds tightly to SHBG, about 54% binds loosely to albumin, and only 2 to 3% remains unbound as free testosterone. That free fraction is the biologically active portion that enters cells and activates androgen receptors.

Because SHBG levels vary widely between individuals, two men with identical total testosterone numbers can have very different amounts of bioavailable hormone. A 2017 analysis in the Journal of Clinical Endocrinology & Metabolism (N=10,453 men from the Framingham Heart Study and other cohorts) demonstrated that calculated free testosterone correlated more strongly with clinical symptoms of hypogonadism than total testosterone did [1]. The 2018 Endocrine Society guideline on male hypogonadism recommends measuring total testosterone first, then reflexing to free testosterone (or SHBG for calculation) when total testosterone falls in the borderline range of 264 to 400 ng/dL [2].

Timing matters, too. Testosterone follows a circadian pattern, peaking between 6 AM and 10 AM and dropping 20 to 25% by afternoon in younger men [3]. The Endocrine Society and the American Urological Association both specify morning, fasting samples, repeated on at least two separate days before diagnosing hypogonadism.

Free Testosterone and SHBG: The First Add-Ons

Free testosterone and SHBG should be the first tests paired with total testosterone. Without them, your clinician is reading a partial story.

SHBG rises predictably with aging, hepatitis, hyperthyroidism, and anticonvulsant use, while it drops with obesity, insulin resistance, nephrotic syndrome, and exogenous androgens. A man with a total testosterone of 380 ng/dL and an SHBG of 65 nmol/L may have genuinely low free testosterone, while the same total testosterone with an SHBG of 20 nmol/L may represent adequate androgen exposure. The calculated free testosterone (using the Vermeulen equation with SHBG and albumin) is preferred over direct analog free testosterone assays, which the Endocrine Society has repeatedly flagged as unreliable [2].

If your lab offers only direct free testosterone, interpret with caution. Equilibrium dialysis is the gold-standard measurement but is rarely available outside research settings. Most clinicians order SHBG plus albumin and use a validated online calculator.

LH and FSH: Primary vs. Secondary Hypogonadism

These two pituitary hormones are non-negotiable when testosterone is low. Skip them and you cannot determine the cause.

Luteinizing hormone (LH) stimulates Leydig cells in the testes to produce testosterone. Follicle-stimulating hormone (FSH) drives spermatogenesis through Sertoli cells. When total testosterone is low and LH/FSH are elevated (typically LH >9.4 mIU/mL), the pituitary is working hard but the testes are failing. That pattern defines primary hypogonadism, seen in Klinefelter syndrome, post-chemotherapy damage, varicocele, or age-related testicular decline [4].

When total testosterone is low and LH/FSH are low or inappropriately normal, the pituitary is not sending adequate signal. This is secondary (central) hypogonadism. Causes include pituitary adenomas, chronic opioid use, obstructive sleep apnea, obesity, and exogenous steroid use. A 2014 study in Endocrine Reviews reported that opioid-induced androgen deficiency affects 21 to 86% of men on chronic opioid therapy, depending on formulation and dose [5].

The distinction matters clinically because secondary hypogonadism may respond to clomiphene citrate or address the underlying cause, while primary hypogonadism generally requires testosterone replacement directly.

Estradiol: The Aromatization Check

Testosterone converts to estradiol through the aromatase enzyme, concentrated in adipose tissue. Ordering the sensitive estradiol assay (LC-MS/MS, sometimes listed as "estradiol, ultrasensitive") alongside testosterone provides two pieces of information.

First, a baseline estradiol above 40, 50 pg/mL in a symptomatic man suggests significant aromatization, often driven by visceral adiposity. High estradiol can suppress GnRH through negative feedback, compounding the testosterone deficit. Second, once testosterone therapy begins, estradiol monitoring every 3 to 6 months helps detect excessive aromatization that can cause gynecomastia, water retention, and mood disturbance.

The Endocrine Society does not set a firm upper estradiol threshold for men on TRT, but most specialist clinicians use 40, 50 pg/mL as a practical action point for considering dose adjustment or aromatase inhibitor discussion [2]. The standard immunoassay for estradiol was designed for female-range values and loses accuracy below 20 pg/mL, which is why the sensitive assay matters in male patients.

CBC and Hematocrit: The Safety Net

A complete blood count is the most important safety lab for any man considering or receiving testosterone therapy. Period.

Testosterone stimulates erythropoietin production. Hematocrit rises in virtually all men on TRT, and polycythemia (hematocrit >54%) is the single most common adverse effect, reported in 5 to 18% of men on injectable testosterone in clinical studies [6]. The Endocrine Society recommends checking hematocrit at baseline, at 3 to 6 months after initiating therapy, and annually thereafter [2]. A hematocrit exceeding 54% warrants dose reduction, switch to a shorter-acting formulation, or therapeutic phlebotomy.

Baseline hemoglobin also catches pre-existing anemia, which may itself be a consequence of hypogonadism. A 2017 JAMA Internal Medicine trial (the Testosterone Trials, TTrials, N=788) demonstrated that testosterone gel increased hemoglobin by a mean of 1.0 g/dL in anemic men with unexplained anemia of aging [7].

Metabolic Panel, Fasting Glucose, and HbA1c

Hypogonadism and metabolic syndrome run in parallel. Ordering a comprehensive metabolic panel, fasting glucose, and HbA1c alongside testosterone captures this overlap.

A 2016 meta-analysis in Diabetes Care including 28 observational studies found that men with type 2 diabetes had total testosterone levels approximately 2.7 nmol/L (78 ng/dL) lower than age-matched controls without diabetes [8]. The relationship is bidirectional: low testosterone predicts incident type 2 diabetes, and insulin resistance suppresses gonadotropin secretion. The EMAS (European Male Ageing Study, N=3,369) confirmed that waist circumference and insulin resistance were the strongest predictors of low testosterone, surpassing age itself [9].

From a practical standpoint, a fasting glucose above 126 mg/dL or HbA1c above 6.5% uncovered during a testosterone workup changes the treatment plan entirely. Dr. Bradley Anawalt, professor of medicine at the University of Washington and a co-author of the Endocrine Society hypogonadism guideline, has noted: "You cannot manage male hypogonadism effectively without addressing concurrent metabolic disease. Weight loss of 5 to 10% can raise total testosterone by 50 to 100 ng/dL in obese men, sometimes eliminating the need for replacement."

A lipid panel is also appropriate. The relationship between testosterone and cardiovascular risk was clarified by the TRAVERSE trial (N=5,246), a randomized, placebo-controlled study published in the New England Journal of Medicine in 2023, which found that testosterone replacement in men 45 to 80 years old with hypogonadism and cardiovascular risk factors did not increase major adverse cardiovascular events over a median 33-month follow-up [10].

Prolactin: Ruling Out Pituitary Pathology

A prolactin level should accompany every initial testosterone panel, especially when LH and FSH return low.

Prolactinomas (prolactin-secreting pituitary adenomas) are the most common functioning pituitary tumors. They suppress GnRH pulsatility, causing secondary hypogonadism with symptoms that overlap completely with primary low testosterone: low libido, erectile dysfunction, fatigue, and reduced muscle mass. A prolactin level above 100 ng/mL strongly suggests a macroprolactinoma and warrants pituitary MRI [4].

Mild prolactin elevations (25 to 100 ng/mL) can also result from medications, particularly antipsychotics, metoclopramide, and SSRIs. Catching this on the initial panel prevents misattributing the hypogonadism to aging or lifestyle factors when the cause is pharmacologic and reversible.

Thyroid Function: TSH and Free T4

Hypothyroidism and hypogonadism share a symptom profile that includes fatigue, weight gain, depression, decreased libido, and cognitive fog. Without a TSH and free T4, your clinician may initiate testosterone therapy for a condition that would respond better to levothyroxine.

Hypothyroidism also increases SHBG, which can lower free testosterone independently of gonadal function [11]. Conversely, hyperthyroidism raises SHBG dramatically, sometimes producing total testosterone in the high-normal range while free testosterone is low. A baseline thyroid panel prevents both misdiagnosis and misinterpretation of the testosterone result.

PSA and the Prostate Consideration

The Endocrine Society recommends a baseline PSA in men over 40 before starting testosterone therapy and monitoring at 3 to 12 months, then per standard screening guidelines [2].

Testosterone does not cause prostate cancer. The saturation model, proposed by Abraham Morgentaler, MD, and supported by data from multiple cohort studies, posits that androgen receptors in prostate tissue become fully saturated at relatively low testosterone levels (approximately 250 ng/dL), and additional testosterone does not produce further proliferative stimulus [12]. The TRAVERSE trial safety data confirmed no significant increase in high-grade prostate cancer incidence in the testosterone arm [10].

A pre-treatment PSA above 4.0 ng/mL (or above 3.0 ng/mL in high-risk populations) should trigger urologic evaluation before initiating therapy. This is not because testosterone causes cancer, but because undiagnosed existing cancer is a contraindication to exogenous androgens per current guidelines.

The Recommended Panel at a Glance

For a man presenting with symptoms of hypogonadism, the following laboratory panel covers diagnostic, etiologic, and safety needs before treatment begins:

Diagnostic: total testosterone (morning, fasting), free testosterone or SHBG plus albumin for calculation, LH, FSH.

Etiologic and differential: prolactin, TSH and free T4, estradiol (sensitive assay), ferritin (to rule out hemochromatosis, a commonly missed cause of secondary hypogonadism).

Safety and metabolic baseline: CBC with differential, comprehensive metabolic panel, fasting glucose, HbA1c, lipid panel, PSA (men >40).

Some clinicians also order DHEA-S, cortisol (AM), and insulin levels depending on the clinical picture. For men with suspected Klinefelter syndrome (tall stature, small testes, gynecomastia, azoospermia), a karyotype should follow.

How to Interpret Results in Context

Numbers need context. A total testosterone of 350 ng/dL in a 70-year-old with no symptoms is not the same finding as 350 ng/dL in a 35-year-old with fatigue, erectile dysfunction, and documented infertility.

The Endocrine Society defines male hypogonadism as consistently low morning total testosterone below 264 ng/dL (9.2 nmol/L) on at least two separate samples, combined with signs and symptoms [2]. The AUA uses a threshold of 300 ng/dL. Both agree that borderline values require free testosterone measurement and clinical correlation.

Dr. Shalender Bhasin, professor of medicine at Harvard Medical School and principal investigator of the TTrials, has stated: "The diagnosis of hypogonadism should not be based on a single testosterone measurement. Acute illness, sleep deprivation, excessive exercise, and even a poor night of sleep can transiently lower testosterone by 10 to 15%."

Repeat testing on a separate morning, in a fasted state, after adequate sleep, is the minimum standard before diagnosis. The companion labs described in this article turn a single number into a clinical picture.

What Total Testosterone Means for Women

While this article focuses on male hypogonadism evaluation, total testosterone is also measured in women presenting with hirsutism, acne, alopecia, or suspected polycystic ovary syndrome (PCOS). The normal range for women is 15 to 70 ng/dL, and an elevated level should prompt additional testing including DHEA-S, 17-hydroxyprogesterone, and androstenedione [13]. SHBG is equally important in female testosterone interpretation, as oral contraceptives raise SHBG significantly and can mask hyperandrogenism.